Skip to Main Content
DownloadHi-Res Photo

Christina Price, MD

Assistant Professor of Medicine (Immunology) and of Pediatrics (Immunology); VA Medical Center Section Chief, Allergy and Clinical Immunology; Clinical Chief of Allergy and Immunology, Rheumatology, Allergy, & Immunology; Associate Program Director Fellowship, Allergy and Clinical Immunology

Contact Information

Christina Price, MD

Mailing Address

  • Allergy & Clinical Immunology

    PO Box 208013

    New Haven, CT, 06520-8013

    United States

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

immune deficiency in autoimmunity.

Coauthors

Selected Publications

  • Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.Azmy V, Kaman K, Tang D, Zhao H, Dela Cruz C, Topal JE, Malinis M, Price CC. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. Journal Of Clinical Immunology 2021, 41:738-747.
  • Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest 2020, 158:1397-1408.
  • Subtle But Clinically Significant: A Review of Antibody Deficiency in AdultsHarada K, Price C. Subtle But Clinically Significant: A Review of Antibody Deficiency in Adults, Clin Pulm Med. 26(3):71-75 May
  • Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom D, Lucena JM, Seidl M, Schmitt-Gräff A, Reiser V, Emmerich F, Frede N, Bulashevska A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Sumnik Z, Sediva A, Slatter M, Arkwright PD, Cant A, Lorenz HM, Giese T, Lougaris V, Plebani A, Price C, Sullivan KE, Moutschen M, Litzman J, Freiberger T, van de Veerdonk FL, Recher M, Albert MH, Hauck F, Seneviratne S, Schmid JP, Kolios A, Unglik G, Klemann C, Speckmann C, Ehl S, Leichtner A, Blumberg R, Franke A, Snapper S, Zeissig S, Cunningham-Rundles C, Giulino-Roth L, Elemento O, Dückers G, Niehues T, Fronkova E, Kanderová V, Platt CD, Chou J, Chatila T, Geha R, McDermott E, Bunn S, Kurzai M, Schulz A, Alsina L, Casals F, Deyà-Martinez A, Hambleton S, Kanegane H, Taskén K, Neth O, Grimbacher B. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. The Journal Of Allergy And Clinical Immunology 2018, 142:1932-1946.
  • Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long?Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long? The Journal Of Allergy And Clinical Immunology 2015, 136:1407-9.
  • Optimizing Care for Patients With Adverse Events From Immunotherapeutics.Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. Cancer Journal (Sudbury, Mass.) 2020, 26:537-542.

Clinical Trials

ConditionsStudy Title
Immune SystemRESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
Edit Profile